Please login to the form below

Not currently logged in
Email:
Password:

EU clears AbbVie's leukaemia drug venetoclax

Becomes the first BCL-2 inhibitor to be approved by the EMA

European Union 

AbbVie has been given a green light from the EMA for their chronic lymphocytic leukaemia (CLL) drug venetoclax, the first BCL-2 inhibitor to be approved in the EU.

The drug will be sold as Venclyxto in Europe and has been given a conditional approval for the treatment of adult CLL patents who have 17p deletion or TP53 mutation and have either failed chemoimmunotherapy or are unsuitable for treatment with a B-cell receptor pathway inhibitor such as AbbVie and Johnson & Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib). It can also be used to treat CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

The 17p deletion or TP53 mutation, which is seen in around 10% of all newly-diagnosed patients with this form of cancer and is a difficult-to-treat form of the disease, typically associated with poor prognosis.

The conditional approval comes on the back of two phase II trials, which found a 79% over response rate ORR) in previously-treated patients and a 64% ORR in patients who had been previously treated with and failed ibrutinib or idelalisib.

The two companies have a phase III study called MURANO evaluating Venclexta in a broader set of relapsed/refractory CLL patients that is due next year. If positive, that could support a filing for an expanded label covering all relapsed/refractory CLL patients.

Venetoclax was first launched in the US earlier this year as Venclexta, and is also approved in Argentina, Puerto Rico and Canada. It is predicted to become a blockbuster by 2020, with Credit Suisse suggesting sales in the year will reach $1.16bn.

Around two-thirds of that total will from CLL and a third from follow-up indications such as non-Hodgkin lymphoma (NHL) and acute myeloid leukaemia (AML), say the analysts.

Venetoclax is being developed by AbbVie and Roche, and is sold jointly by the companies in the US and by AbbVie alone elsewhere.

Article by
Phil Taylor

9th December 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Getting the most out of your agency - a guide to developing a dynamic and rewarding relationship with your agency partner
...
Empowering nurses to transform patient care
As Sustainability and Transformation Plans (STPs) turn to action across England, Page & Page’s Communications Director Cori Hollenbach explores whether healthcare companies are considering the influence nurses can have on...
digital health stock resized
Making digital health personal
What makes a tool successfully support adherence and deliver value-based care?...

Infographics